Keqian Bio intends to sign a joint vaccine research and development agreement with Huazhong Agricultural University
June 12, 2025
Source: drugdu
51
June 10, Keqian Biology(688526) announced that it plans to sign a "Swine Mycoplasma Pneumonia, Swine Flu" contract with Huazhong Agricultural UniversityA joint research and development agreement on a two-inactivated vaccine (XJ03 strain + HN strain + SD strain) for H1N1 and H3N2.
This transaction constitutes a related-party transaction, as a wholly-owned subsidiary of Huazhong Agricultural University holds 16.73% of the company's shares, and many directors have direct ties with the university. Both parties will jointly bear the various experimental expenses, technical achievements and intellectual property rights required during the research and development process.Belong to both parties jointly.
In the first quarter of 2025, Keqian Bio achieved revenue of 245 million yuan and net profit attributable to shareholders of the parent company of 108 million yuan.
https://finance.eastmoney.com/a/202506103426820044.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene July 4, 2025
- Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch July 4, 2025
- this is the path to carbon neutrality July 4, 2025
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA July 4, 2025
- Rare, Recurrent, and Still a Challenge July 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
